Sermorelin
Sermorelin acetate (GHRH 1-29)
Sermorelin is a synthetic 29-amino acid peptide that mimics the biologically active portion of growth hormone releasing hormone (GHRH). Originally FDA-approved in 1997 as Geref® for treating children with growth hormone deficiency, it stimulates the pituitary gland to produce natural growth hormone in physiological pulsatile patterns. Unlike direct growth hormone injections, sermorelin works with the body's feedback mechanisms to prevent overdose and maintain natural GH rhythms.
Complete Research Database
0
Major Studies
0
Total Participants
3
Research Articles
N/A
Years of Research
Safety Analysis
Adverse event data from clinical trials
Generally Well-Tolerated
Adverse Event Frequencies
Low (<10%)Moderate (10-25%)High (>25%)
18%
Moderateinjection site reactions
10%
Lowfacial flushing
7%
Lowheadache
6%
Lowfatigue
5%
Lowdizziness
4%
Lownausea
Clinical Safety Notes
Timing
GI side effects typically occur during dose escalation
Severity
Most adverse events are mild to moderate in severity
Adherence
Discontinuation rate due to side effects: ~5.3%
Safety
No increased risk of pancreatitis in clinical trials
Monitoring
Regular monitoring recommended for thyroid function
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.